What is Nabsys?
Nabsys is dedicated to enhancing the understanding of diseases, improving diagnostic accuracy, and ultimately elevating patient outcomes. The company achieves this by enabling routine, cost-effective analysis of genomic structural variations. Based in Providence, RI, Nabsys comprises a growing team of scientists and engineers focused on pioneering advancements in genomic analysis. Their mission is to make sophisticated genomic insights accessible for broader clinical application, positioning them at the forefront of precision medicine.
How much funding has Nabsys raised?
Nabsys has raised a total of $117.5M across 13 funding rounds:
Series C
$10M
Debt
$4.7M
Grant
$244K
Private Equity
$25.5M
Private Equity
$6M
Other Financing Round
$21M
Debt
$150K
Private Equity
$38M
Series C (2011): $10M, investors not publicly disclosed
Debt (2012): $4.7M, investors not publicly disclosed
Grant (2012): $244K supported by Internal Revenue Service
Private Equity (2014): $25.5M featuring Bay City Capital and Rose Ventures, Inc
Private Equity (2016): $6M backed by Jilin Zixin Pharmaceutical Industrial Co., Ltd
Other Financing Round (2019): $21M with participation from Hitachi High-Technologies Corporation
Debt (2020): $150K led by PPP
Private Equity (2022): $38M supported by Hitachi High-Tech Corporation
Key Investors in Nabsys
Hitachi High-Tech Corporation
Hitachi High-Tech Corporation, a prominent entity in trading and industrial machinery, has participated in Nabsys's funding rounds, indicating a strategic interest in advanced technological applications within the life sciences sector.
Jilin Zixin Pharmaceutical Industrial Co., Ltd
Jilin Zixin Pharmaceutical Industrial Co., Ltd, a Chinese pharmaceutical company involved in the research, development, and production of medicines and gene sequencers, brings a unique perspective to Nabsys's investor base, potentially bridging pharmaceutical applications with genomic insights.
Slater Technology Fund
The Slater Technology Fund, a dedicated seed-stage investor in Rhode Island, has supported Nabsys, demonstrating a commitment to fostering early-stage technological ventures and contributing to the region's innovation ecosystem.
What's next for Nabsys?
The recent major strategic investment in Nabsys signals a new phase of expansion and technological development. With a history of securing diverse forms of capital, including grants, debt, and significant equity rounds, the company is well-positioned to scale its operations and further refine its genomic analysis platform. This latest financing is likely to fuel research and development, enhance market penetration, and solidify Nabsys's competitive edge in the rapidly evolving field of genomics and diagnostics. The company's trajectory suggests a strong focus on commercialization and broader adoption of its innovative solutions.
See full Nabsys company page
